Drug-resistant tuberculosis (DR-TB) is challenging to diagnose, treat, and prevent, but this
situation is slowly changing. If the world is to drastically reduce the incidence of DR-TB, we …

Background Treatment of drug-susceptible tuberculosis (TB) conducted under strong
national TB programs (NTPs) using standard 4-drug therapy and directly observed therapy …

The continuing spread of drug-resistant tuberculosis (TB) is one of the most urgent and
difficult challenges facing global TB control. Patients who are infected with strains resistant …

Even in the 21st century, we are losing the battle against eradication of tuberculosis (TB). In
2015, 9.6 million people were estimated to have fallen ill with TB, of which 1.5 million people …

Tuberculosis (TB) strains with rifampicin or multidrug resistance (defined as, at least,
combined rifampicin and isoniazid resistance)–MDR/RR-TB–require more complex, costly …

For three decades, drug-resistant tuberculosis (TB) has posed grave challenges to patients,
communities and global TB control efforts. Treatment of multidrug-resistant (MDR)-TB (ie TB …

Highlights•Management of tuberculosis is complicated by high levels of drug resistance in
some regions of the world.•Increasingly, molecular diagnostics are being used for resistance …

The emergence of antimicrobial resistance against Mycobacterium tuberculosis, the leading
cause of mortality due to a single microbial pathogen worldwide, represents a growing threat …

The need for new tuberculosis (TB) diagnostics has never been greater as TB in the HIV‐
infected is often sputum smear negative or extrapulmonary and may progress rapidly unless …

Tuberculosis (TB) remains the foremost cause of death by an infectious disease globally.
Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB; resistance to rifampicin and …